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Compulsory license of pharmaceutical products in the Trade Related Aspects of Intellectual Property 
Rights (TRIPs) Agreement attempts to balance the interest of patent holders and The right to 
health. The access of medicines in developing countries for the epidemic diseases, such as, HIV/AIDS  
medicine is crucial to  protect The right to health. The objective of the research is to analyze com-
prehensively the legal implication  of compulsory license for the pharmaceutical product to the 
protection of The right to health in developing countries. It is  a normative juridical research by ap-
plying conceptual and  comparative approaches. The results of the research  shows that: first, the 
implementation of compulsory licence is in accordance with the international human right law: 
second, the legal implication of the compulsory license  causes the adoption of policy and regulati-
ons regarding the protection of the right to health in developing countries, such as Indonesia, Ma-
laysia, Brazil, India and  South Africa.  
 




Lisensi wajib produk farmasi dalam perjanjian perdagangan yang terkait dengan HKI berusaha 
menyeimbangkan kepentingan pemegang hak paten dan perlindungan hak kesehatan di negara ber-
kembang. Akses terhadap obat di negara berkembang yang mengalami wabah penyakit seperti HIV/ 
AIDs sangat penting untuk melindungi hak kesehatan di negara berkembang. Tujuan penelitian ini 
untuk menganalisa secara komprehensif implikasi hukum lisensi wajib terhadap perlindungan hak 
kesehatan di negara berkembang. Penelitian ini merupakan penelitian yuridis normatif dengan pende-
katan konseptual dan komparatif, serta dianalisa secara deskriptif kualitatif dan disajikan secara des-
kriftif. Adapun hasil penelitian ini ialah: pertama, implementasi lisensi wajib dalam Perjanjian TRIPs 
di negara berkembang terhadap produk parmasi sesuai dengan ketentuan hukum hak asasi manusia 
internasional; kedua implikasi hukum lisensi wajib terhadap produk parmasi di negara berkembang 
menyebabkan obat-obat yang penting untuk penyembuhan HIV/AIDs mudah diakses  dan harganya 
terjangkau, seperti misalnya  di Indonesia, Malaysia, Brasil, India and  Africa Selatan untuk melindu-
ngi hak atas kesehatan. 
 




 Developing countries are suffering from 
expensive essential medicines to secure deadly 
diseases such as HIV/AIDs. For example, World 
Health Organization (WHO) reports1 show that 
                                                          
Ω  The article is part of individual research, funded by Fa-
culty of Law Universitas Islam Indonesia by Decree 
Number 1/Kaprodi/70/Div.URT/TU/H/6/20l7. 
1  Chuan-Feng Wu, “Transnational Pharmaceutical Corpo-
rations' Legal and Moral Human Rights Responsibilities 
in Relation to Access to Medicines”, Asian Journal of 
infectious diseases kill over 14 million people 
per year, 90% of whom live in a developing or 
newly industrialized society.2 Among them, ap-
proximately three million people die annually 
from HIV/AIDS, two million from tuberculosis, 
and one million from malaria.3 
                                                                                       
WTO & International Health Law & Policy, Vol. 7, 2012, 
p. 78. 
2   Ibid. 
3  Ibid 
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There are many states become the par-
ties of international human rights instruments 
which recognized the rights to health, as well 
as the parties of Trade Related Aspect of Intel-
lectual Property Rights Agreement (hereinafter 
TRIPs Agreement). One of the patented medici-
nes is Antiretroviral which is able to secure the 
lethal disease, such as HIV/AIDS.4 From the 
perspective of intellectual property right Law, 
an expensive price of patented medicine, such 
as “antiretroviral’ is reasonable since the phar-
maceutical industries have already invested a 
huge capital and technology to create the me-
dicine.  In order to protect their products, they 
patented their products so they have the ex-
clusive right5 to determine the price and prohi-
bit the other parties to produce without their 
consent.  
On the other hand, patients in develop-
ing countries really deserve the medicine, but 
they do not have capability to purchase the 
medicine. Consequently, the government of the 
developing countries failed to perform the obli-
gation to protect, to fulfil and to promote the 
right to health which is stipulated in the Inter-
national Coveant on Social, Economic and Cul-
tural rights (hereinafter ICESCR).6 However, 
the World Trade organization (hereinafter 
WTO) as an international trade organisation 
states that it is necessary to regulate the ac-
cess of the essential medicine, so that it can be 
purchased by the patients in developing coun-
tries including Indonesia by exercising compul-
sory license. The paper urgently attempts to 
examine the relationship between compulsory 
                                                          
4  Senai W. Andemariam, “The Cleft-Stick between Anti-
Retroviral Drug Patents and HIV/AIDS Victims: An In-
Depth Analysis of the WTO's Trips Article 31 Bis Amend-
ment Proposal of 6 December 2005”, Intellectual Pro-
perty Quarterly, Vol. 4, 2007, p. 415.  
5  Lilian Martins, “The Right to Health Versus the Right to 
Property: Conflicts Between Public Welfare and Private 
Interests, the Brazilian Approach”, Law & Business Re-
view of the Americas, Vol. 20, Summer 2014, p. 484.  
6   Emily M. Cowleya, “The Right to Health: Guatemala's 
Conflicting Obligations Under The Central American 
Free Trade Agreement and The International Covenant 
On Economic, Social, and Cultural Rights”, Michigan 
State University Journal of Medicine & Law, Vol. 11, 
2007,  p. 231. 
 
license and the protection of the right to 
health. 
In addition, the implementation of com-
pulsory license in developing countries some-
times causes protest from developed countries 
since the compulsory license may jeopardize 
the interest of the patent holder of the essen-
tial medicines in developed countries. Howe-
ver, the developing countries have to find prac-
tical reasons to implement compulsory license 
in order not to contradict the requirements of 
the TRIPs Agreement. One of the efforts to be 
performed by the developing countries is to 
adopt national policy regulations to implement 
compulsory license, such us to define what na-
tional emergency situation, non-commercial 
used and the mechanism of the compulsory li-
cense in the national law.  
The problems of this article are: first. 
is the compulsory license of pharmaceutical 
product in the TRIPs Agreement in accordance 
with the right to health in international human 
right law?;  second, what is the legal implicati-
on of compulsory license regarding  pharmaceu-
tical product in the TRIPs Agreement to the 
protection of the right to health in developing 
countries?. Thus, the aim of the research is to 
analyse comprehensively the legal implication 
of compulsory license pharmaceutical product 
in the TRIPs Agreement to the protection of the 
right to health in developing countries.  
 
Research Methods  
This library research belongs to normati-
ve research which uses secondary data consist-
ing of primary legal material, secondary legal 
material and tertiary legal material. Then, the 
approaches employed in the research are con-
ceptual approach and comparative approach. 
The conceptual approach is used to understand 
the concept of compulsory license and the re-
lationship with the concept of the right to 
health, while comparative approach is employ-
ed to examine the implementation of compul-
sory license in some developing countries, such 
as, Indonesia, Malaysia, Brazil, India and South 
Africa. All the collected materials are grouped 
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based on each variable and qualitatively analy-
zed and descriptively presented.  
 
Discussion 
Compulsory License of Pharmaucitical Pro-
duct in the TRIPs Agreement based on Inter-
national Human Rights Law Perspective 
The TRIPs Agreement does not explicitly 
mention the term compulsory license in the 
text but Article 31 is understood to allow com-
pulsory license and government use without au-
thorization of the right holder.7 Article 31 of 
the TRIPs Agreement states: “Where the law of 
a Member allows for other use of the subject 
matter of a patent without the authorization of 
the right holder, including use by the govern-
ment or third parties authorized by the govern-
ment, there are some following provisions shall  
be respected”,  such as, Article 31 (a), (b), (f) 
and (j): 
(a) authorization of such use shall be 
considered on its individual merits; 
(b) such use may only be permitted if, 
prior to such use, the proposed user 
has made efforts to obtain authoriza-
tion from the right holder on reason-
able commercial terms and conditi-
ons and that such efforts have not 
been successful within a reasonable 
period of time. This requirement may 
be waived by a Member in the case of 
a national emergency or other cir-
cumstances of extreme urgency or in 
cases of public noncommercial use. In 
situations of national emergency or 
other circumstances of extreme ur-
gency, the right holder shall, never-
theless, be notified as soon as rea-
sonably practicable.In the case of 
public non-commercial use, where 
the government or contractor, with-
out making a patent search, knows or 
has demonstrable grounds to know 
that a valid patent is or will be used 
by or for the government, the right 
holder shall be informed promptly; 
                                                          
7   Timothy Bazzle, “Pharmacy of the Developing World: 
Reconciling Intellectual Property Rights in India with 
The Right To Health: Trips, India's Patent System and 
Essential Medicines”, Georgetown Journal of Interna-
tional Law, Vol. 42, 2011, p. 788 
(f) any such use shall be authorized pre-
dominantly for the supply of the do-
mestic market; 
(j) any decision relating to the remune-
ration provided in respect of such use 
shall be subject to judicial review or 
other independent review by a dis-
tinct higher authority in that Mem-
ber; 
 
Article 31 does not hamper the grounds on 
which compulsory licensing is allowable, and it 
become the authority of states to determine 
the balance of the protection of patent holders 
and the interest of the patients. Article 31(b) 
provides that this limitation may be waived by 
a Member in the event of a national emergen-
cy. Unfortunately, there is no explanation what 
constitute national emergency in the TRIPs 
Agreement. The Contracting Parties of the 
TRIPs Agreement have a freedom to define 
what national emergency is. For example, the 
endemic of HIV/AIDs which occur in a develop-
ing country can be considered as national 
emergency. Article 6 of the International 
Health Regulations (2005) (IHR) imposes an ob-
ligation on countries to notify WHO, via the 
National IHR Focal Point, of “all events which 
may constitute a public health emergency of 
international concern within its territory”.1The 
IHR define a “public health emergency of inter-
national concern” as an extraordinary event 
that is determined to “constitute a public 
health risk to other States through the inter-na-
tional spread of disease and to potentially re-
quire a coordinated international response”. 
World Health Organization (WHO) Chapter 11: 
Public health Emergencies Summary Points.8 
Thus, there is no uniform definition of the na-
tional emergency. The definition of national 
emergency is based on the national policy and 
interest of each state.   
One of the most important restrictions is 
adopted in Article 31(f) - the use of commercial 
license should be “predominantly for the supply 
of the domestic market.” The term “predomi-
nantly” in Article 31(f) implies that some ex-
                                                          
8   WHO, without years, Health Law, retrieved on:  http:// 
www.who.int/healthsystems/topics/health-
law/chapter11.pdf Accessed on  January10th, 2018. 
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portation under compulsory license from the 
exporting nation could not be allowed to be ex-
ported to other countries which do not have 
the capacity to produce the medicine. Based on 
Article 31 (f) It is clear that initiates  a problem 
in the implementation of compulsory license in 
developing countries which do not have the 
capability to produce medicine.  
There are many developing countries 
which do not have the capacity to produce the 
essential medicine, thus, it is necessary to find 
a solution to solve the problem. Consequently, 
the fourth WTO Ministerial Conference, held in 
November 2001 in Doha, Qatar, adopted a Dec-
laration on TRIPS and Public Health (herein-
after Doha Declaration) which affirmed the so-
vereign right of governments to take measures 
to protect public health.9 Based on the Doha 
Declaration, the Member of the TRIPs Agree-
ment has a freedom to implement and to in-
terpret the Provision of the TRIPs Agreement to 
support the public health.   
Article 5 (c) Doha Declaration recognizes 
the flexibility of the TRIPs Agreement provides 
a freedom to state to determine what kind of 
legal basis to grant compulsory license and to 
determine the national emergency which are 
various from one state to another state to 
protect public health.10 Thus, Article 5 of the 
Doha Declaration has to be read in the light of 
article 6 of the Doha Declaration which gives 
opportunity to states to carry out parallel im-
port.11 This term refers to “a practice in which 
a third party imports a product marketed in a 
foreign country by the patent holder, in com-
petition with the product that same patent hol-
der imports or manufactures locally”.12 
                                                          
9   Holger Hestermeyer, “Human Rights and the WTO: The 
Case of Patents and Access to Medicines”, International 
Trade Law & Regulation, Vol. 14 No. 6, 2008, p. 126. 
10  Mohammad Towhidul Islam, “TRIPs Agreement and Pub-
lic Health: Implications and Challenges for Bangla-
desh”, International Trade Law & Regulation, Vol. 17 
No. 1, 2011, p. 22. 
11  Samira Guennif and Julien Chaisse, “Present Stakes 
Around Patent Political Economy: Legal and Economic 
Lessons from the Pharmaceutical Patent Rights in 
India”, Asian Journal of WTO & International Health 
Law & Policy, Vol. 2 No. 1, March, 2007, p. 75. 
12  Charles T. Collins-Chase, “The Case Against Trips-Plus 
Protection in Developing Countries Facing Aids Epide-
On August 30, 2003, the WTO General 
Council for TRIPs resolved the dispute on im-
plementing the Doha Declaration by adopting a 
decision which essentially permitted a patent 
exception rule to allow countries to produce 
medicine for export to fulfill public health 
needs in countries that do not have production 
capacities.13 Finally, in order, the decision has 
a legal obligation to the Member States of 
WTO, on 6 December 2005, the WTO issued a 
Protocol to amend Article 31(f) become Article 
31 (f) bis of the TRIPs Agreement which allows 
parallel import.14  
 
The Righ to Health in the International Hu-
man Right Law 
Article 25(1) of the UDHR  affirms that 
“everyone has the right to a standard of living 
adequate for the health of himself and of his 
family, including food, clothing, housing and 
medical care and necessary social services.”15   
Hence, based on Article 25 (1) UDHR, a state 
has obligation to achieve the standard stipula-
ted on the Article. Besides, there are some In-
ternational instruments, which regulate the 
rich to health, such as Article 12 (1) of the In-
ternational Covenant on Economic, Social, and 
Cultural Rights (hereinafter ICESCR).16 Article 
5(e) (iv) of the International Convention on the 
Elimination of All Forms of Racial Discrimina-
tion of 1965, and  Articles 11 (1) (f) and 12 of 
the Convention on the Elimination of All Forms 
                                                                                       
mics”, University of Pennsylvania Journal of Internatio-
nal Law, Vol. 29, Spring 2008, p. 768. 
13  Sartika Nanda Lestari, “Implementasi Compulsory Li-
censing Terhadap Obat-Obatan Dalam Bidang Farmasi di 
Indonesia (Studi Berdasarkan Doha Declaration on The 
TRIPs Agreement and Public Health)”, Thesis Program 
Magister Ilmu Hukum Fakultas Hukum Universitas Dipo-
negoro, Semarang 2012. p. 77, retrieved from the web-
site: http://eprints.undip.ac.id/42149/1/Bab_I-II.pdf, 
aaccessed on November 4, 2017.  
14  World Trade Organization, without Years, Amendment 
of the TRIPS Agreement’, WT/L/641, 8 December 2005 
Amendment, retrieved on website:  https://www.wto. 
org/english/tratop_e/trips_e/wtl641_e.htm, accessed 
on November 4, 2017. 
15  Tina S. Bhatt, “Amending Trips: A New Hope For Increa-
sed Access to Essential Medicines”, Brooklyn Journal of 
International Law, Vol. 33, 2008, p. 600. 
16  Kojo Yelpaalaa, “Quo Vadis WTO? The Threat of Trips 
and the Biodiversity Convention to Human Health and 
Food Security”, Boston University International Law 
Journal, Vol. 30, 2012, p. 65-66. 
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of Discrimination against Women (hereinafter 
CEDAW) of 1979.17  
Access to medicine affects the right to 
health. The fundamental legal basis the right to 
health is stipulated in the article 12 (1) of  
ICESCR, which recognizes “the right of every-
one to the enjoyment of the highest attainable 
standard of physical and mental health.” Con-
sequently it needs the active effort of a state 
to materialize it, which includes the preven-
tion, treatment and control of epidemic, ende-
mic, occupational and other diseases and the 
creation of conditions which would assure to all 
medical service and medical attention in the 
event of sickness.18  
Related to the health policy in Indonesia, 
as one of the examples of developing countries, 
health is one of the eleven priorities in the 
national development program. It is stipulated 
in the Regulation of the President of the Re-
public of Indonesia Number 5 of 2010 on the 
National Medium –Term Development Plant 
(RPJMN) 2010-2015. Furthermore, the right to 
health is also recognized as human right based 
on Act Number 36 Year 2009 regarding Health. 
Article 5 (1) Act number 36 Year 2009 states: 
“Every people shall have equal right in obtain-
ing access to health resources”. Thus, it beco-
mes the obligation of the government of Indo-
nesia how to fulfill the right of the people. It 
has been stipulated in Article 16 Act Number 36 
Year 2009: “The Government shall be responsi-
ble for the availability of fair and proportional 
distributed resources of health19 for all people 
in order to achieve maximum health degree. 
Thus, it can be submitted that the health policy 
of Indonesia is in accordance to the General 
                                                          
17  Timothy Bazzle, loc.cit. 
18  Adam Houstona, “A Scientific Approach to Intellectual 
Property and Health: Innovation, Access, and a Forgot-
ten Corner of the Universal Declaration of Human 
Rights”, John Marshall Review of Intellectual Property 
Law, Vol. 13, 2014, p. 800-801. 
19  Article 1 (2) Act, Number 36 Year 2009, it states: “Re-
sources of health refers to any kind of fund, power, 
health supply, pharmacy supply and health equipments 
as well as health service facilities and technology used 
to maintain health efforts made by the Government, lo-
cal government, and/or the people”.  
Comment No 14 of the Highest Commissioner of 
Human Rights.20 
In its General Comment No. 14 on the 
“Right to the Highest Attainable Standard of 
Health,” the Economic, Social and Cultural 
Rights Committee (hereinafter ESCR Commit-
tee”) explained that all health care facilities, 
goods, and services including medications and 
the provision thereof should be: (1) available in 
sufficient quantity; (2) accessible to everyone 
without discrimination; (3) acceptable in the 
sense of respectful of medical ethics and cus-
toms; and (4) of good quality and scientifically 
appropriate.21 Thus, it is essential to materia-
lize those accessibility of the right to health by 
providing easy access and affordable essential 
medicine which is demanded by the patients. 
 
Conflict or Congruence between Compulsory 
License of pharmaceutical Product in the 
TRIPs Agreement and  the Protection of  the 
Right to Heath in Developing Countries 
TRIPs Agreements are auspicious steps 
toward making access to HIV/AIDS medicine be-
comes  a reality for developing nations.22 The 
WTO negotiations and agreements outstanding-
ly avoid any obvious recognition of human 
rights, particularly the right to health. The 
TRIPs Agreement more focus on  public health 
rather than the discussion  to the protection of  
individual human rights, such as the right to 
health.23 Consequently, it  results in less effec-
                                                          
20  Office of the Highest Commissioner of Human Rights, 
CESCR General Comment No. 14:  The Right to the Hig-
hest Attainable Standard of Health (Art. 12). Adopted 
at the Twenty-second Session of the Committee on 
Economic, Social and Cultural Rights, on 11 August 2000 
(Contained in Document E/C.12/2000/4), retrieved on:                                                                                      
http://www.refworld.org/pdfid/4538838d0.pdf, Acces-
sed on November 4, 2017. 
21-  Rudolf V. Van Puymbroeck, “Basic Survival Needs And 
Access To Medicines-Coming To Grips With TRIPs: Con-
version + Calculation”, Journal of Law, Medicine & 
Ethics, Vol. 38, Fall 2000, p. 521-522. 
22   Erika Georgea,” The Human Right to Health and HIV/ 
AIDs: South Africa and South-South Cooperation to Re-
frame Global Intellectual Property Principles and Pro-
mote Access to Essential Medicines”, Indiana Journal of 
Global Legal Studies, Vol. 18, winter 2012, p. 179-180. 
23  Chuan-Feng Wu “Raising the Right to Health Concerns 
Within the Framework of International Intellectual Pro-
perty Law”, Asian Journal of WTO & International 
Health Law & Policy, Vol. 5, 2010, p. 144-145. 
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tive laws to achieve access to HIV/AIDS medici-
nes. 
The majority of TRIPs Agreement Mem-
bers are also the Members of ICESCR, thus, the-
re is possibility of conflict between the obliga-
tions in the TRIPs Agreement and the obligation 
in the ICESCR. At glance, the two agreements 
regulate two different things; the TRIPs Agree-
ment regulates intellectual property right while 
ICESCR regulates the protection of human right. 
Actually, the two Agreements interrelate since 
the access of medicine affects the protection 
to the right to health. The TRIPs Agreement 
should be flexibly interpreted to promote ac-
cess to medicine.24 The Doha Declaration opens 
the way for developing countries to access es-
sential medicine.  
 
The Legal Implication of Compulsory License 
of pharmaceutical Products in the TRIPs 
Agreement to the Protection of the Right to 
Heath in Developing Countries 
Compulsory license which has been regu-
lated based on the TRIPs Agreement and also 
Doha Declaration causes some legal implicati-
ons in developing countries to access to medici-
ne in order to protect the right to health. First, 
one of the legal implication is the accessibility 
and affordability of the essential medicine 
which are deserved by patients in developing 
countries, such as Antiviral and Antiretrovi-
ral,25 since the developing countries can use 
the justification based on the reason of pro-
tecting public health and also the developing 
countries have a freedom to issue the law to 
determine what emergency situation to justify 
to implement compulsory license. Thus, the 
compulsory license enables state to protect the 
right to health 
Second, the developing countries can 
exercise the compulsory license to support the 
right to health. However, it is necessary to 
adopt policy and regulations to take the benefit 
of the compulsory license to protect the right 
to health. Indeed, the right to health does not 
only oblige states to take positive measures to 
                                                          
24  Chuan-Feng Wu,  op.cit, p. 81-82.  
25  Adam Houstona, op.cit, p. 802. 
ensure the access to affordable medicine for 
all, but also requires them to refrain from ta-
king measures that could impede this access. 
Consequently, when implementing compulsory 
license rules, countries have to take the right 
to health into account, ensuring the access to 
quality medicines is affordable prices,26 so that 
the patients in developing countries will not 
find difficulty in accessing the medicine.  
Third, access to essential medicine which 
is protected by patent has already become the 
important issue in international human rights 
law. The accessibility and affordability of es-
sential medicine needs to be materialized in 
order to protect the right to health.27 It has 
been noted by the UN Sub-Commission on 
Human Rights28 that there are apparent con-
flicts between the fundamental principles of 
international human rights and the principles of 
international intellectual property regime as 
embodied in the TRIPS Agreement.  Thus, the 
compulsory license can be used as a legal ins-
trument to justify of producing generic version 
of essential medicines in developing countries.  
Hence, the TRIPs Council made an Amendment 
of the TRIPs Agreement in November 2005 
which permits the parallel import. 
Finally, international human rights docu-
ments cannot serve as a substitute for an expli-
cit recognition of the right to medicine in the 
TRIPS Agreement. By embodying the right in 
the TRIPS Agreement, the WTO would help se-
cure the right to medicine by supplying Member 
                                                          
26  Center for Health, “Transnational Pharmaceutical Cor-
porations' Legal and Moral Human Rights Responsibili-
ties in Relation to Access to Medicines”, “Health and 
Human Rights Resource Guide”. retrieved from:  
https://www.hhrguide.org/2017/06/09/access-to-
medicines-and-human-rights/. Accessed on November 
4, 2017. 
27  Peter K. Yua, “Intellectual Property in International 
Perspective: Institute for Intellectual Property & Infor-
mation Law Symposium”, Houston Law Review, Vol.46, 
2009, p. 990. 
28  WTO Doha Ministerial Declaration on the TRIPS Agree-
ment and Public Health, WT/MIN(01)/DEC/2 (14 Nov. 
2001) [hereinafter Declaration on TRIPS and Public 
Health]; WTO Council for TRIPS, Implementation of Pa-
ragraph 6 of the Doha Declaration on the TRIPS Agree-
ment and Public Health, IP/C/W/405 (30 Aug. 2003) 
[hereinafter WTO, Implementation of Paragraph 6]”. 
Available on the website: https://www.wto.org/eng-
lish/res_e/booksp_e/ddec_e.pdf, retrieved on June 7, 
2017. 
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States with a legal justification for implement-
ing patent laws that do not impede access to 
essential medicines. Hence, the compulsory li-
cense is the gate way to embody protection of 
the right to health in developing countries, if 
the developing countries can performed the 
legal instrument which is in accordance with 
the TRIPs Agreement. 
 
Legal Implication of Compulsory License by  
State Practicses to Protect the Right to 
Health in Some Developing Countries 
The right to health has been recognized 
as part of human right and as constitutional 
right in most developing countries. On the ot-
her hand, as the Members of the TRIPs  Agree-
ment in the WTO, states have obligation to har-
monize the national intellectual property right 
law in accordance with the TRIPs Agreement. In 
order to analyse further the legal implication of 
compulsory license to the protection of the 
right to health in developing countries, the re-
search analyses briefly the legal implication of 
compulsory license in five developing coun-
tries, namely  Indonesia, Malaysia, Brazil, South 
Africa and India. 
First, the legal implication of compulsory 
license of pharmaceutical products in indonesia 
in order to protect the right to health. The 
right to health in Indonesia is not explicitly sti-
pulated in the Indonesian Constitution and Act 
Number 36 Year 2009 on Health. The right to 
health can be found in  Article 28 H (1) Indo-
nesian Constitution, and Article 62 Human Right 
Act which regulates the right to have health 
service. However, when the Indonesian govern-
ment would like to protect the right to health 
in Indonesia, they have to comply with the 
TRIPs Agreement. Hence, the Indonesian go-
vernment have already amended the Patent Act 
in accordance with the TRIPs Agreement. The 
reason of exercising compulsory license in Indo-
nesia is based on Article 109 Indonesian Patent 
Act. However, unlike Malaysia which imported 
generic versions of the drugs from India, Indo-
nesia used the compulsory license to appoint 
local manufacturers to produce 7 medicines for 
treating Hepatitis B and HIV/AIDs based on 
Decree of the President Republic of Indonesia 
No 76 of 2012.29    
Second, the legal implication of Compul-
sory License of Pharmaceutical Products in Ma-
laysia in order to protect the Right to Health. 
The right to health in Malaysia is recognized as 
a human right and also as Constitutional right 
in the Federal Constitution.30 The Malaysian go-
vernment seriously concerns and protects the 
right to health. Thus, when there is an epide-
mic case of HIV/AIDS in Malaysia which can be 
considered as national emergency, the govern-
ment of Malaysia issued compulsory license for 
the medicine to secure the patients because 
the price of the medicine is very expensive. 
Malaysia was the first Asian country that har-
monized its legislation31 with the Doha Declara-
tion and the 2003 Decision.   
Based on the compulsory license regulat-
ed in the TRIPs Agreement, Malaysia can take 
advantages of the mechanism. Under Section 
84 of the Malaysian Patents Act, it allows the 
grant of compulsory licence in case of national 
emergency or in public interest. Based on this 
provision, Malaysia issued the license to import 
generic Antiretroviral (ARV) medicines from In-
dia, and this measure has certainly helped the 
country bring down the cost of treatment.32 
Third,  the Iegal implication of Compul-
sory License of Pharmaceutical Products in Bra-
zil in order to protect the Right to Health. The 
Brazilian Constitution of 1988 granted the right 
to health to all citizens and mandated the cre-
ation of a national health-care system. Thus, 
when there is an epidemic case of HIV/AIDS in 
Brazil which can be considered as national 
emergency, the government of Brazil issued 
compulsory license for the medicine to secure 
                                                          
29  Helmi Khair, “Is The Right to Health Undermined by 
The Agreement of Trade-Related Aspects of Intellectual 
Property Rights? Journal of Academia UiTM Negeri 
Sembilan, Vol. 4, 2016, p. 30.  
30  Ibid. 
31  Raadhika Gupta, “Compulsory Lisencing under TRIPs: 
How Far it Addresses Public Health Concern in Deve-
loping Nations, Journal of Intellectual Property Rights, 
Vol. 15, September 2010, p. 362. 
32   Samira Guennif and Julien Chaisse, op.cit, p. 79-80. 
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the patients,33 because the price of the medi-
cine is costly. However, it should bear in mind 
that Brazil is the member of the TRIPs Agree-
ment; consequently, Brazil has to comply with 
the TRIPs Agreement in exercising the compul-
sory license. Based on Article 31 (b) TRIPs Ag-
reement, Brazil has consistently taken a positi-
on in favor of public health in trying to nego-
tiate a balance between pharmaceutical IPR 
and access to medicine.34 
Fourth, the Iegal implication of compul-
sory license of pharmaceutical products in 
South Africa in order to protect the Right to 
Health. South Africa is estimated to have the 
highest absolute number of people living with 
HIV of any country in the world, it is also home 
to the world’s largest public sector antiretro-
viral (ARV) treatment programme.35 Access to 
medicines is an essential component of the 
right to health. Undoubtedly, the challenge 
ahead is to ensure that the South African go-
vernment is equipped with a public health-sen-
sitive legal framework that can achieve the pri-
ce reductions needed to sustain a public HIV 
treatment programme and ensure all people’s 
access to medicines.36 Indeed, South Africa as 
the member of the TRIPs Agreement, its Patent 
Act has to comply with the TRIPs Agreement.  
Unfortunately, Africa does not take ad-
vantage of the compulsory license which is 
adopted in Article 31 TRIPs Agreement since 
South Africa feared retaliation from other 
countries37 especially United States. Thus, what 
has been done by the South African government 
only make bilateral agreement with United 
State to get reducing price of the essential me-
dicine, especially in a national emergency si-
tuation dealing with epidemic HIV/AIDS and its 
                                                          
33  Anna Dontje,” Rethinking Trips: The Future of Pharma-
ceutical Patents”, Wisconsin International Law Journal, 
Vol. 33, Fall, 2015, p. 388. 
34  Ibid. 
35  Erika George, “The Human Right to Health And HIV/ 
AIDs: South Africa and South-South Cooperation to Re-
frame Global Intellectual Property Principles and Pro-
mote Access to Essential Medicines”, Indiana Journal of 
Global Legal Studies, Vol. 38, Winter, 2011, p. 168. 
36  Ibid. 
37  Siobhán Elizabeth Stade Murillo, Fair Or Fraud: Has The 
Protocol Amending Trips Flourished Or Failed?”, Indiana 
International & Comparative Law Review, Vol. 27, 
2017. P. 198. 
citizens does not have capability to afford the 
medicine.  
Fifth, the Iegal implication of compulso-
ry license of pharmaceutical products in India 
in order to protect the Right to Health. The 
Constitution of India has provisions regarding 
the right to health. The Constitution incorpora-
tes provisions guaranteeing everyone’s right to 
the highest attainable standard of physical and 
mental health.38 In Indian Constitution does not 
explicitly recognize the fundamental right to 
health. However, Article 21 of the Constitution 
of India guarantees a fundamental right to life 
and personal liberty.  
The Indian Patent Act of 1970 prohibited 
the patent ability of pharmaceutical products 
in order to boast the availability of low-cost 
medicines.  However, the Act allowed patents 
on the manufacturing process of said products. 
As a result  of the Act India turn out to be the 
largest manufacturer and provider of generic 
pharmaceutical products in the world. Howe-
ver, when India becomes the member of the 
TRIPs Agreement, India has to comply with the 
TRIPs Agreement. The TRIPS Agreement, al-
though attempting to establish uniformity of in-
ternational patent law, allowed each individual 
country to establish its standards of patent 
ability as long as the standards did not violate 
the agreement.  
Accordingly,  Article 31 of the TRIPS Ag-
reement, without stating the words “compul-
sory license,” establishes a procedure by which 
a compulsory license could be granted if cer-
tain conditions were met. The Patent Act of 
1970 was amended in 2005. The legal implica-
tion of the Compulsory license causes the Indi-
an Patent Act has to be harmonized with the 
TRIPs Agreement.39 
Thus, it is reasonable that the implemen-
tation of compulsory license for essential medi-
                                                          
38  Indrajit Khandekar et al, “Right to Health Care”, Jour-
nal Indian Acad Forensic Med, Vol. 34 No. 2. April-June 
2012, p. 160. 
39  Javier Esparza, “Indian Patent Law: Working Within the 
TRIPs Agreement Flexibilities to Provide Pharmaceu-
tical Patent Protection While Protecting Public Health”, 
retrieved from: http://heinonline.org/HOL/Landing 
Page?handle=hein.journals/jtrnlwp24&div=8&id=&page
=. Accessed on 19 December 2017. 
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cine in order to protect, to fulfill and to pro-
mote the right to health. Provisions related to 
the grant of compulsory license in India are 
prescribed under Sections 82-94 (Chapter XVI) 
of the Patents Act, 1970, and Rules 96-102 
(Chapter XIII) of the Patents Rules, 2003.40 Ho-
wever, in issuing Compulsory license India also 
refers to the International TRIPs Agreement Ar-
ticle 31 and its Amendment and Doha Decla-
ration. The Compulsory license is issued in the 
circumstances of national emergency or in cir-
cumstances of extreme urgency or in case of 




The compulsory license of pharmaceuti-
cal product in the TRIPs Agreement is in accor-
dance with the protection of the right to health 
in international human right law. It can be pro-
ven from the efforts that have been done by 
WTO to harmonize the protection of patent 
holders and the protection of the right to 
health by providing compulsory license mecha-
nism in the TRIPs Agreement and the Doha Dec-
laration as well as the amendment of of TRIPs 
Agreement in November 2005. In the mean ti-
me, the international instruments of human 
rights, such as UDHR and ICESCR established 
the protection of the right to health for all 
people. However, the developing countries as 
the member of the TRIPs Agreement, they have 
their own policy and national regulations to re-
gulate the implementation of the compulsory 
license. The developing countries utilize the 
compulsory license scheme to protect the right 
to health.  
The legal implication of compulsory li-
cense regarding pharmaceutical products in the 
TRIPs Agreement to the protection of the right 
to health in developing countries has caused 
accessibility and affordability of essential me-
dicine to secure deadly disease, such as HIV/ 
AIDs in developing countries.  Indonesia, Malay-
                                                          
40  Vipin Mathur et.al, “Compulsory Licensing of Pharma-
ceutical Patents In India: A Research Study”,  “Euro-
pean Journal of Pharmaceutical and Medical Research, 
Vol. 3, 2016, p. 537. 
sia, Brazil, South Africa and India recognize the 
right to health in their Constitution. Hence, in 
order to protect, to fulfill and to promote the 
right to health for their citizens, they issued 
compulsory licence. The Doha Declaration clari-
fies the right of WTO Members to incorporate 
flexibility built into the TRIPS Agreement into 
their domestic intellectual property laws to 
protect and promote the right to health. The-
refore, the direct legal implication of exerci-
sing compulsory license in developing countries 
has already enabled the developing countries 
to establish the policy and national regulations 
how to regulate compulsory license in the na-
tional level and also to utilize the compulsory 
license to protect the right to health. 
 
Suggestion 
The legal implication of the Compulsory 
license of pharmaceutical products in develop-
ing countries to the protection of the right to 
health in developing countries are not so diffe-
rent among the developing countries. However, 
since there are different situation and conditi-
on of each developing country, specific policy 
of each developing country to deal with the 
deadly disease, such as HIV/AIDs from one 
country to another country is required. Thus, 
the following suggestions are proposed: firstly, 
each developing country has to regulate the 
compulsory license in its national law especially 
when determining the national emergency, pa-
rallel import and  non commercial use of the 
essential medicine; secondly, in order to pre-
vent disputes among  developing countries and 
the pharmaceutical industries in developed 
countries, the government involvement in de-
veloped countries is needed to encourage the 
pharmaceutical industries to participate in the 
protection of the right to health. 
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